DuraGraft: saphenous vein graft flushing and storage, purpose-built for the intraoperative window.
Intraoperative flushing and storage for saphenous vein grafts, from harvesting through grafting, at room temperature, for up to 4 hours.
DuraGraft is the first and only FDA De Novo granted solution for flushing and storing saphenous vein grafts during coronary artery bypass graft (CABG) surgery. It holds the harvested vein in a physiologically balanced, isotonic environment at room temperature for up to four hours, from harvest through anastomosis. It replaces the flushing and storage solution already in your workflow, with no protocol change.
A physiologically balanced environment for a graft that has none.
DuraGraft is a physiologically balanced, isotonic solution that maintains pH, osmolality, and ionic balance, supporting the structural integrity and cell viability of saphenous vein grafts from harvest through anastomosis.
Specific salts and organic components (normal constituents of blood) create a non-oxidizing, pH-balanced environment during the ischemic period.
No protocol changes required.
Evidence behind the solution.
FDA De Novo review: preclinical viability and morphology
Two FDA authorizations, and no competing cleared product.
DuraGraft holds two separate FDA authorizations. The De Novo grant created a new device classification for intraoperative vein graft protection. The later 510(k) clearance added room temperature storage, which takes the product out of the cold chain and onto the OR shelf, supplied through hospital procurement channels rather than the pharmacy pathway. No competing FDA-cleared product exists for this indication.
FDA De Novo granted. DEN230002, Class II. The first device classification of its kind for intraoperative vein graft protection.
510(k) clearance for room temperature storage at 20 to 25°C (68 to 77°F), eliminating the cold chain.
Prescription use. Two-component kit mixed at the point of use, covering the entire intraoperative window.
Measurable patient and hospital value from day one.
All benefits below are listed in the Instructions for Use, as provided by the FDA to the Company. Wall thickness is a biomarker, and its clinical significance as a surrogate for long-term graft patency has not been established.
- Reduced wall thickening, the earliest detectable sign of vein graft disease
- Prevention of oxidative damage, slowing progression of vein graft failure
- Oxidative damage is the primary mediator of ischemic reperfusion injury
- Reduction of oxidative damage maintains the structural and functional integrity of vascular conduits
- Associated with lower mortality at 3 years in an observational propensity-matched comparison (Caliskan et al., 2024). This does not establish causation.
- Increased storage time of 4 hours at controlled room temperature, 20 to 25°C (68 to 77°F)
- No change in training or surgical procedure. Seamless integration, no protocol changes required
- Increased savings through reduction of repeat procedures and hospital stays
- Readily available in the operating suite. Direct OR shelf placement drives adoption and increases utilization
- Sold directly through hospital procurement channels rather than the hospital pharmacy pathway
- No cold warehouse storage or shipping, with substantial cost savings passed to distributors and end users